Amycretin
Last updated
GLP-1 and amylin receptor agonist. Once weekly (injectable); once daily (oral).
Other GLP-1 medicines at sellers we link to

Lowest compounded tirzepatide on a monthly plan, not FDA-approved
$69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

Lowest compounded semaglutide on a monthly plan, not FDA-approved
$59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before
No seller we link to sells amycretin; these are different medicines, compounded and not FDA-approved. Those sellers pay us if you buy, which never changes a price we show.
Catalog reviewed Nov 4, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.
Data updated . What changed
Average weight lost in its trials
- 60 mg weekly (Phase 1b/2a)Phase 1b/2a (subcutaneous) · 36 wks−24.3% (thelancet.com/journals/lancet/article/PIIS0140-6736(25)01185-7/abstract) (-24.3% at 36 wks · Phase 1b/2a (subcutaneous) · 60 mg weekly (Phase 1b/2a))about 49 lb at 200 lb
Averages from separate trials, so they are not a head-to-head ranking and not a prediction. Pounds apply the percentage to a 200 lb starting weight.
Investigational: not FDA-approved for this or any use. It is still being studied in trials.
What to know about Amycretin
An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.
- Mean weight change in the cited trial
- −24.3% (thelancet.com/journals/lancet/article/PIIS0140-6736(25)01185-7/abstract) (-24.3% at 36 wks · Phase 1b/2a (subcutaneous) · 60 mg weekly (Phase 1b/2a))
Phase 1b/2a (subcutaneous) · 60 mg weekly (Phase 1b/2a)
- FDA shortage report
- In development
Investigational. Not FDA-approved.
- Route & frequency
- Once weekly (injectable); once daily (oral)
Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.
Investigational uses
Amycretin (investigational)
Obesity; type 2 diabetes (investigational)
An investigational single molecule that agonizes both the GLP-1 and amylin receptors, in development as both a once-weekly injection and a once-daily oral tablet.
Dosing, warnings & contraindications
Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.
No approved label (investigational)
Amycretin is investigational. See its registered studies below. Search DailyMed (dailymed.nlm.nih.gov).
Clinical trials
1 registered trials indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.
- A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity (clinicaltrials.gov/study/NCT06049329)NCT06049329PHASE1Completed36 enrolled
Source: ClinicalTrials.gov API v2 (clinicaltrials.gov/search) · as of Nov 17, 2026
All trials on ClinicalTrials.gov (clinicaltrials.gov)Related GLP-1s to compare
Latest Amycretin trials and reviews
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study (pubmed.ncbi.nlm.nih.gov/40550231)
Randomized trial · Lancet · Jun 20, 2025 · Dahl K et al. · cited by 70
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial (pubmed.ncbi.nlm.nih.gov/40550229)
Randomized trial · Lancet · Jun 20, 2025 · Gasiorek A et al. · cited by 37
Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.